N¹,N⁴-bis(2-nitrophenyl)butane-1,4-diamine | 93250-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N¹,N⁴-bis(2-nitrophenyl)butane-1,4-diamine
• 英文别名: N,N'-bis(2-nitrophenyl)butane-1,4-diamine
• CAS: 93250-37-4
• 化学式: C₁₆H₁₈N₄O₄
• 分子量: 330.343
• InChiKey: QUCNHMMAIUUVFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  568.6±45.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N¹,N⁴-bis(2-nitrophenyl)butane-1,4-diamine 在 溶剂黄146 、 锌 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N,N'-(butane-1,4-diylbis(1H-benzo[d]imidazole-1,2-diyl))bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamide)
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS
  [FR] COMPOSÉS CHIMIQUES

  摘要：

  本文披露了作为跨膜蛋白173（TMEM173）调节剂的化合物，也被称为STING（干扰素基因刺激剂），以及通过给哺乳动物施用这种化合物来治疗乙型肝炎病毒相关疾病的方法。

  公开号：

  WO2020202091A1
• 作为产物：
  描述：

  四亚甲基二胺 、 1-氟-2-硝基苯 生成 N¹,N⁴-bis(2-nitrophenyl)butane-1,4-diamine
  参考文献：
  名称：

  UNUSUAL KINETIC BEHAVIOR OF BIS-FLAVIN FORN-BENZYL-1,4-DIHYDRONICOTINAMIDE (BNAH) REDUCTION IN AN AQUEOUS SOLUTION

  摘要：

  我们合成了几种连接在异咯嗪环 10,10′ 位上的双黄素。研究发现，双黄素中每个黄素的反应活性都会受到分子内另一个黄素分子的很大影响，这取决于双黄素的构象。

  DOI：

  10.1246/cl.1983.1281

文献信息

• Bis (benzimidazole) derivatives serving as potassium blocking agents
  申请人：Neurosearch A/S

  公开号：US06194447B1

  公开（公告）日：2001-02-27

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  这项发明涉及新型钾通道阻滞剂，以及它们在制备药物组合物中的应用。 此外，该发明针对用于治疗或缓解与钾通道活性相关的疾病或障碍的药物组合物，特别是哮喘、囊性纤维化、慢性阻塞性肺病和鼻涕、痉挛、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱排出道梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠状动脉心脏病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡症、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、缺席性癫痫发作、肌肉肌无力症、口干症、糖尿病II型、胰岛素过多症、早产、秃头、癌症和免疫抑制。
• Syntheses and reactivity of bisflavins. Oxidation of N-benzyl-1,4-dihydronicotinamide by flavins in aqueous solution
  作者：Yumihiko Yano、Eiichi Ohya

  DOI：10.1039/p29840001227

  日期：——

  Several bisflavins linked at the 10,10′-positions of isoalloxazine rings have been synthesized. The kinetics of the oxidation of N-benzyl-1,4-dihydronicotinamide in aqueous solution have been examined. It has been found that each flavin of a bisflavin is considerably influenced by another intramolecular flavin moiety due to the formation of a charge-transfer complex between intramolecularly reduced

  已经合成了在异四恶嗪环的10,10'-位连接的几个双黄素。已经研究了N-苄基-1，4-二氢烟酰胺在水溶液中的氧化动力学。已经发现，由于在分子内还原的和氧化的黄素之间形成了电荷转移复合物，因此双黄素的每个黄素都受到另一种分子内的黄素部分的显着影响。复合物的形成取决于构象。
• Models for potential dendritic nitric oxide donors: crystal structures of two 2-nitroanilino precursors and nitric oxide-release behavior of the nitrosated derivatives
  作者：Alec R. Badour、Corey J. Arnett-Butscher、Dillip K. Mohanty、Philip J. Squattrito、Kelly J. Lambright、Kristin Kirschbaum

  DOI：10.1107/s2053229618011737

  日期：2018.9.1

  Two molecular precursors to dendrimeric materials that could serve as slow and sustained NO‐releasing therapeutic agents have been synthesized and characterized. N1,N4‐Bis(2‐nitrophenyl)butane‐1,4‐diamine, C16H18N4O4, (I), crystallizes in a lattice with equal populations of two molecules of different conformations, both of which possess inversion symmetry through the central C—C bond. One molecule

  已经合成并表征了树枝状材料的两种分子前体，它们可以用作缓慢和持续的NO释放治疗剂。N 1，N 4-双（2-硝基苯基）丁烷-1,4-二胺，C 16 H 18 N 4 O 4，（I）结晶成具有两个相同构象的相同分子种群的晶格通过中心的CC键具有反对称性。一个分子中仅具有抗沿着丁基链构象，而另一个具有笨拙在该第一C-C键的取代基的构象。N 2，N2-双[2-（2-硝基苯胺基）乙基] -N 1-（2-硝基苯基）乙烷-1，2-二胺，C 24 H 27 N 7 O 6，（II）在一个不对称单元。相邻的分子对通过N-H…O胺-硝基氢键连接成二聚体。二聚体被组装成以A – B – A – B顺序堆叠的层，使得堆叠方向上的重复距离超过46Å。分子NO释放剂N 1，N 4-双（2-硝基苯基）-N 1，N 4-二亚硝基丁烷-1,4-二胺，C 16 H 16 N 6 O 6，（III）和N 1-（2-硝基苯基）-N
• Synthesis of novel 2,2- and 1,1-linked dimeric ‘head-to-head’ N-alkoxybenzimidazoles
  作者：John M. Gardiner、Andrew D. Goss、Tahir N. Majid、Andrew D. Morley

  DOI：10.1016/s0040-4039(02)02590-x

  日期：2003.1

  Synthesis of two new types of ‘head-to-head’ N,N-alkoxy bisbenzimidazoles is described. The proposed intermediate N-oxy benzimidazole from base-induced heterocyclization of N-alkylnitroanilines can be trapped with a biselectrophile (to give an N,N-linked dimer), or double heterocyclization of dimeric nitroanilines can be intercepted by electrophile trapping of both N-oxybenzimidazole termini to give

  描述了两种新型“头对头” N，N-烷氧基双苯并咪唑的合成。所提出的中间ñ从碱诱导heterocyclization氧基苯并咪唑Ñ -alkylnitroanilines可以用biselectrophile被捕获（以得到Ñ，ñ -连接的二聚体），或二聚体硝基苯胺的双heterocyclization可以通过两者的亲电子俘获被截获ñ -氧苯并咪唑末端得到C2，C2连接的二聚体。这些代表构成新类别的苯并咪唑二聚体的两个区域异构基序。
• Potassium channel blocking agents
  申请人：NeuroSearch A/S

  公开号：US20020049246A1

  公开（公告）日：2002-04-25

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  本发明涉及新型钾通道阻滞剂及其在制备药物组合物中的应用。此外，本发明还涉及用于治疗或缓解与钾通道活性有关的疾病或疾病的药物组合物，特别是哮喘、囊性纤维化、慢性阻塞性肺疾病和流涕、惊厥、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱出流道梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡病、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、失神发作、肌萎缩性肌肉营养不良、干口症、2型糖尿病、高胰岛素血症、早产、秃发、癌症和免疫抑制。